Trial · NCT01752634
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Up to Week 24 (Primary Analysis) | STARTED | Secukinumab (AIN457) 75 mg s.c. | 99 | |
| Up to Week 24 (Primary Analysis) | STARTED | Secukinumab (AIN457) 150 mg s.c. | 100 | |
| Up to Week 24 (Primary Analysis) | STARTED | Secukinumab (AIN457) 300 mg s.c. | 100 | |
| Up to Week 24 (Primary Analysis) | STARTED | Placebo - AIN457 150 mg | 43 | |
| Up to Week 24 (Primary Analysis) | STARTED | Placebo - AIN457 300 mg | 45 | |
| Up to Week 24 (Primary Analysis) | STARTED | Placebo - Not Rerandomized | 10 | |
| Up to Week 24 (Primary Analysis) | COMPLETED | Secukinumab (AIN457) 75 mg s.c. | 93 | |
| Up to Week 24 (Primary Analysis) | COMPLETED | Secukinumab (AIN457) 150 mg s.c. | 95 | |
| Up to Week 24 (Primary Analysis) | COMPLETED | Secukinumab (AIN457) 300 mg s.c. | 97 | |
| Up to Week 24 (Primary Analysis) | COMPLETED | Placebo - AIN457 150 mg | 43 | |
| Up to Week 24 (Primary Analysis) | COMPLETED | Placebo - AIN457 300 mg | 45 | |
| Up to Week 24 (Primary Analysis) | COMPLETED | Placebo - Not Rerandomized | 0 | |
| Up to Week 24 (Primary Analysis) | NOT COMPLETED | Secukinumab (AIN457) 75 mg s.c. | 6 | |
| Up to Week 24 (Primary Analysis) | NOT COMPLETED | Secukinumab (AIN457) 150 mg s.c. | 5 | |
| Up to Week 24 (Primary Analysis) | NOT COMPLETED | Secukinumab (AIN457) 300 mg s.c. | 3 | |
| Up to Week 24 (Primary Analysis) | NOT COMPLETED | Placebo - AIN457 150 mg | 0 | |
| Up to Week 24 (Primary Analysis) | NOT COMPLETED | Placebo - AIN457 300 mg | 0 | |
| Up to Week 24 (Primary Analysis) | NOT COMPLETED | Placebo - Not Rerandomized | 10 | |
| Week 24 to Week 260 | STARTED | Secukinumab (AIN457) 75 mg s.c. | 93 | |
| Week 24 to Week 260 | STARTED | Secukinumab (AIN457) 150 mg s.c. | 95 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01752634/flow